Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Document › Details

BRAIN AG. (9/7/17). "Press Release: BRAIN AG Wins New Long-term Oriented Investor by Way of a Capital Increase. DAH Beteiligungs GmbH Is New, Long-term Oriented Investor of BRAIN AG Supporting Its Growth Strategy". Zwingenberg.

Organisations Organisation BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
  Today BRAIN Biotech AG
  Group BRAIN Biotech (Group)
  Organisation 2 DAH Beteiligungs GmbH
  Group HOPP Group (family of Dietmar Hopp)
Products Product industrial biotechnology
  Product 2 finance
Index term Index term BRAIN Biotech–Hopp Group: investment, 201709 capital increase 1.641m new shares placed with new investor DAH Beteiligungs GmbH
Persons Person Eck, Jürgen (BRAIN 201507–201912 CEO before CTO + Co-founder LEFT 1/20)
  Person 2 Hopp, Daniel (DAH Beteiligungs GmbH)

> Capital increase by approximately 10% from Authorized Capital

> Proceeds from capital increase planned to be used for new acquisition

Today, the bioeconomy company BRAIN AG has successfully implemented a capital increase against contributions in cash, partially using its Authorized Capital. A total of 1,641,434 new registered no-par-value shares („New Shares“), corresponding to approximately 10% of the current share capital, was subscribed by one long-term oriented investor; the DAH Beteiligungs GmbH from Mannheim, Germany.

Dr Juergen Eck, CEO of BRAIN AG, says: „In our discussions with Daniel Hopp, the long-term nature and sustainability of his investment strategy was expressed. The investment of DAH Beteiligungs GmbH, coming on board about one and a half years after our successful IPO, is another important milestone in our growth strategy. We enable the biologisation of classical industrial processes and the corresponding development of new products. The aim is to reduce the dependency on valuable, limited raw materials in favour of more sustainability, nature and climate protection. Examples of this are our DOLCE program for the reduction of sugar consumption, our BioXtractor system for the extraction of precious metals from waste streams, or the use of the greenhouse gas carbon dioxide as a raw material.“

Due to the capital increase, the company’s share capital will increase from currently EUR 16,414,348.00 to EUR 18,055,782.00. The gross proceeds for BRAIN from this transaction will amount to approximately EUR 28 million.

Frank Goebel, CFO of BRAIN AG, says: „BRAIN has been pursuing a successful growth strategy for several years. The goal is, in addition to intensifying research collaborations with industrial partners, to develop and market our own biotechnological product candidates. In line with this strategy, the proceeds from the capital increase shall primarily be used to finance small and medium-sized acquisitions. Consequently, also our shareholders will benefit from our sustainable corporate strategy.”

Further information

Ad hoc release capital


Thomas Deichmann
Head of Public Relations
Phone +49 (0) 62 51 / 9331-72

Record changed: 2023-06-05


Picture Twist Bioscience Biopharma Solutions Our Gold Standard 650x200px

More documents for BRAIN Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top